Who to call at Nuclidium, and when
Fundz watches for the moments Nuclidium starts buying, and tells you who to reach.
- An alert the day Nuclidium raises, hires an executive or expands, scored against what you sell
- The decision-makers there, with verified emails
- Who you already know at Nuclidium, from your own LinkedIn network
Works inside ChatGPT and Claude. Ask who to call at Nuclidium. With Fundz connected, it knows.
NUCLIDIUM and NorthStar Forge Long-term Strategic Partnership to Enhance Copper-67 Radiotheranostic Oncology Pipeline.
Contract Type
partnership
BaselBiotechnologyHealth CareTherapeuticsDescription
NUCLIDIUM AG and NorthStar Medical Technologies, LLC have entered a strategic partnership to advance NUCLIDIUM's Copper-67 radiotheranostic programs. NorthStar will provide production and manufacturing services for Copper-67, supporting various therapeutic applications from clinical development to commercialization.
Quick answer
NUCLIDIUM and NorthStar Forge Long-term Strategic Partnership to Enhance Copper-67 Radiotheranostic Oncology Pipeline. (October 19, 2026). Nuclidium is based in Basel, Basel City, Switzerland.
- What agreement did Nuclidium announce on October 19, 2026?
- NUCLIDIUM AG and NorthStar Medical Technologies, LLC have entered a strategic partnership to advance NUCLIDIUM's Copper-67 radiotheranostic programs. NorthStar will provide production and manufacturing services for Copper-67, supporting various therapeutic applications from clinical development to commercialization.
- What does Nuclidium do?
- Nuclidium is a clinical-stage biotechnology company based in Basel, Switzerland, developing innovative copper-based radiopharmaceuticals for the diagnosis and treatment of cancer.
- Where is Nuclidium based?
- Nuclidium is based in Basel, Basel City, Switzerland.
- Which similar companies announced agreements around the same time?
- Prothena Corporation (October 20, 2026), RxMP Therapeutics (October 20, 2026), YD Bio Limited (October 20, 2026) and Genmab A/S (October 24, 2026) also announced agreements within 45 days of Nuclidium.
Source: Fundz verified event record.
Other recent agreements in Therapeutics and Biotechnology
Contracts and agreements at companies in the same sectors within 45 days, from Fundz verified event records.
- Prothena Partners with Roche to Advance Prasinezumab for Parkinson's Disease Treatment. (October 20, 2026)
- DARPA Awards Up to $10.7 Million Contract to RxMP Therapeutics for Development of RMP-402. (October 20, 2026)
- YD Bio and EG BioMed Form Partnership with JoiiUp to Launch AI Cancer Risk Assessment for Corporate Wellness. (October 20, 2026)
- Genmab and Incyte collaborate on a colorectal cancer trial using petosemtamab and a mutation-targeting drug. (October 24, 2026)
- Menarini and Georgiamune Enter $1.1 Billion License Agreement for Cancer Immunotherapy GIM-621. (October 25, 2026)
- GondolaBio and Children’s Tumor Foundation Partner to Enhance Neurofibromatosis Type 1 Program Development. (October 26, 2026)
Related People
Agreement Insights
What this usually meansNuclidium signed a new agreement. Fundz surfaces partnerships and contracts as they are announced.
145 of these a day, filtered to the companies you pick, with the decision-maker attached.
5 screens from a live account. No signup.